3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Pancreatic Neoplasms
71
Breast Neoplasms
45
Neoplasms
29
Carcinoma, Non-Small-Cell Lung
29
Triple Negative Breast Neoplasms
21
Neoplasm Metastasis
14
Adenocarcinoma
13
Squamous Cell Carcinoma of Head and Neck
8
Lung Neoplasms
8
Colorectal Neoplasms
8
Melanoma
7
Carcinoma
7
Head and Neck Neoplasms
6
Digestive System Neoplasms
6
Cholangiocarcinoma
6
Small Cell Lung Carcinoma
5
Parkinson Disease 4, Autosomal Dominant Lewy Body
5
Pancreatic Diseases
5
Pancreatic Adenocarcinoma
5
Ovarian Neoplasms
5
Digestive System Diseases
5
Carcinoma, Pancreatic Ductal
5
Stomach Neoplasms
4
Sarcoma
4
Recurrence
4
Neoplasms by Site
4
Gallbladder Neoplasms
4
Fallopian Tube Neoplasms
4
Endocrine Gland Neoplasms
4
Carcinoma, Squamous Cell
4
Interventions
patritumab
1
Istiratumab
1
Gemcitabine
1
Albumin-Bound Paclitaxel
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Fibromatosis, Gingival, 2
×
130-nm albumin-bound paclitaxel
×
Clear all
NCT02399137
2018-09-18
CARRIE
Merrimack Pharmaceuticals
Phase 2
Completed
88 enrolled